Subcutaneous injections of cabotegravir plus rilpivirine long-acting in virally suppressed adults with HIV-1
Pharmacokinetics and efficacy were similar between CAB+RPV LA subcutaneous and intramuscular administration; however, due to the higher incidence and duration of ISRs, along with lower tolerability and acceptability of subcutaneous injections, subcutaneous administration with the current CAB LA and RPV LA formulations is not being evaluated further.
Authors
- Conn Harrington
- Susan L. Ford
- Marty St Clair (ORCID: https://orcid.org/0000-0002-8983-2115)
- Herta Crauwels (ORCID: https://orcid.org/0000-0002-4516-8830)
- Rebecca DeMoor
- William Spreen (ORCID: https://orcid.org/0000-0002-8180-1517)
- Rodica Van Solingen‐Ristea (ORCID: https://orcid.org/0000-0003-2301-7430)
- Enrique Bernal (ORCID: https://orcid.org/0009-0001-1753-9104)
- Sherene Min
- Nasir Jamil
- Kelong Han (ORCID: https://orcid.org/0000-0001-8010-9898)
- Johannes Lombaard
- Carolina Acuipil (ORCID: https://orcid.org/0009-0008-7672-3818)
- Ronald D’Amico (ORCID: https://orcid.org/0000-0003-0828-0222)
- Natasha Patel
- Irina Kolobova
Institutions
- GlaxoSmithKline (United States) (US)
- Hospital Reina Sofía de Murcia (ES)
Publication Details
- Journal
- AIDS
- Published
- 2025-08-08
- DOI
- https://doi.org/10.1097/qad.0000000000004310
- Citations
- 1
- Primary Topic
- Intramuscular injections and effects
- Type
- article
- Field-Weighted Citation Impact
- 2.25